China Vs. Cancer: Coverage For 17 Drugs Unveils Price Pressures, Commercial Battleground
Executive Summary
While cancer drug makers generally applaud the rare reimbursement decision in China, some have pointed to mounting and significant pressure to lower prices, while insiders say the real battle has only just began and that translating the coverage into commercial success will take much more effort.
You may also be interested in...
Roche Rides Partnership, Digital Wave To Widen China Oncology Drug Access
Amid rising cancer incidence in the Asia Pacific region, Roche tells Scrip in this exclusive interview that it is going "beyond the pill" to widen access to drugs in the increasingly important oncology market.
Eight For 8: Things You Need To Know About China Biopharma Commercial In 2018
From AI to IPOs, from access models to mobile payments, China’s biopharma sector increasingly became a global leader in biotech financing and digital health innovation in 2018. Here is Scrip's pick of eight key events that captured the major developments in China’s dynamic, highly fluid biopharma commercial scene throughout the year.
Ready, Set, Go: China To Use Patient-Reported Outcomes In Clinical Studies
As a part of real-world evidence, patient-reported outcomes can serve to evaluate a drug's efficacy against primary or secondary endpoints and also reflect safety and quality of life, notes a just-released draft regulation from China’s Center for Drug Evaluation.